Shares of Moderna (MRNA) lost 11% on Wednesday after it presented new data on its RSV vaccine, mResvia, at a CDC advisory committee meeting. Investors were also not impressed with this committee’s recommendation on RSV vaccines and believe that the target market for RSV vaccinations in the country has been narrowed.This new data, which was shared with the CDC’s Advisory Committee on Immunization Practices (ACIP), showed that the vaccine efficacy of mResvia fell sharply in the second year, especially compare ...